New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:28 EDTFRO, BCRX, PF, SPLS, ARO, PFE, PPC, JKS, SDRL, AZN, HSHOn The Fly: Pre-market Movers
HIGHER: Pilgrim's Pride (PPC), up 5% after proposing to acquire Hillshire Brands (HSH) for $45.00 per share cash. Hillshire up 21% following the news, while Pinnacle Foods (PF), which has agreed to be acquired by Hillshire, is down 6.4%... BioCryst (BCRX), up 19% after announcing "positive" results from OPuS-1, a trial of BCX4161... Seadrill (SDRL), up 2.6% after signing investment and cooperation pact with Rosneft and North Atlantic... Aeropostale (ARO), up 11% after $150M financing transaction with Sycamore. LOWER: AstraZeneca (AZN), down 1.7% after downgraded at Societe Generale following Pfizer (PFE) confirming it won't bid for AstraZeneca after rejection of proposal. Pfizer shares are up 1% after the news... Staples (SPLS), down 1% after downgraded at Goldman... Frontline (FRO), down 7.4% after saying it sees weaker Q2 operational results... JinkoSolar (JKS), down 7.8% after reporting lower than expected Q1 earnings results.
News For HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 26, 2015
09:56 EDTBCRXBioCryst management to meet with JPMorgan
Meetings to be held in Boston on January 29-30 hosted by JPMorgan.
09:19 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:59 EDTBCRXBioCryst grants fast track designation for BCX4161
BioCryst announced that the FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. BioCryst is enrolling HAE patients in the OPuS-2 trial of BCX4161; a double-blind, randomized, placebo controlled trial conducted in the U.S. and certain EU countries, with the goal of demonstrating the efficacy and safety of BCX4161 treatment for 12 weeks in approximately 100 patients with HAE. BioCryst expects to report results from OPuS-2 by the end of 2015.
January 25, 2015
13:57 EDTBCRXUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
09:16 EDTSDRLOn The Fly: Pre-market Movers
Subscribe for More Information
08:49 EDTSDRLNorth Atlantic Drilling says Seadrill to back 2018 bond in trade for amendments
North Atlantic Drilling (NADL) announces the launch of an amendment process whereby Seadrill Limited (SDRL) will provide a guarantee for the company's NOK 1.5B bond maturing in 2018, in exchange for some amendments to the bond covenant package, namely replacing the NADL's current financial covenants with Seadrill's financial covenants from Seadrill's NOK denominated bonds. Concurrent with the amendment process for the Bond Agreement, NADL has also launched an amendment process for its secured credit facilities whereby Seadrill Limited will provide a guarantee. Successful conclusion of this process will amend the terms of the loan agreements to align with the terms set forth in Seadrill Limited's loan agreements. "The company's lenders have been supportive thus far and we expect successful conclusion of this amendment in the weeks to come," the company stated. North Atlantic Drilling shares are up 19% in pre-market trading following the announcement.
January 21, 2015
12:30 EDTAZN, PFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
11:21 EDTFROFrontline volatility elevated on wide price movement
Frontline February call option implied volatility is at 130, March is at 158, August is at 133; compared to its 26-week average of 95 according to Track Data, suggesting large near term price movement.
10:54 EDTPPCOptions with increasing implied volatility: PPC EUO GLD
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
13:09 EDTSPLSSources: Staples to spurn Starboard's call to merge with Office Depot, FT says
Subscribe for More Information
10:47 EDTSPLSStaples says will consider 'all actions' that would create shareholder value
Subscribe for More Information
10:45 EDTPPCOptions with increasing implied volatility
Subscribe for More Information
10:23 EDTSPLSStarboard says Staples should explore merger with Office Depot
Starboard Value, one of the largest shareholders of Staples (SPLS), confirmed, as previously reported, that it has delivered a letter to Ronald Sargent, Chairman and CEO of Staples, and the board of directors of Staples. In the letter, Starboard states in part: "As we discussed in our recent meeting, we believe that the best way to maximize value for Staples' shareholders is through exploring and completing a business combination with Office Depot (ODP). For a variety of reasons, we believe that now is the right time to pursue such a transaction, and we urge you to immediately retain a reputable investment bank and legal advisors to assist the Board in evaluating, structuring and executing a transaction with Office Depot. We believe that a strategic combination of Staples and Office Depot would result in synergies that would more than double the operating profits of the combined company and would create an industry-leading office supply retailer that could more effectively compete against larger retailers and online competitors. The magnitude of value creation from such a business combination far exceeds anything that either company could achieve on a standalone basis. We believe that the evidence is clear that shareholders are broadly supportive of a transaction between Staples and Office Depot. As shown in the chart below, since the merger speculation began last September, Staples' share price has risen over 50%, strongly outperforming the S&P 500...After the recent increase in Staples' share price, we believe the stock now trades at a substantial premium to the intrinsic value of the standalone company. This results in a lower cost of capital for Staples and a stronger currency which could be used to acquire Office Depot. If Staples fails to fully explore and consummate a transaction with Office Depot, shareholders will undoubtedly be extremely disappointed...We understand that this will require cooperation from Office Depot, and we have already expressed to them our strong support for a transaction...Our sincere hope is that we can continue to have a constructive dialogue. However, if it becomes clear to us that you have no intention of seriously pursuing this unique and highly attractive opportunity, it would be a clear sign that significant leadership change is needed at Staples."
09:31 EDTSPLSActivist Starboard urging Staples, Office Depot to merge, WSJ reports
Subscribe for More Information
08:59 EDTSPLSStarboard urged Staples to explore Office Depot merger, Bloomberg says
Subscribe for More Information
January 16, 2015
10:27 EDTPPCOptions with increasing implied volatility
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use